Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 18/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 0.97 |
| ▸ | LMNA | P02545 | 1/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.97 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dazoxiben SCHEMBL4427771 | 0.99 | TBXAS1 (0.97) | TBXAS1MEN1LMNAKMT2AKDM4E | |
| Dazoxiben SCHEMBL564080 | 0.99 | TBXAS1 (1.00) | TBXAS1MEN1LMNAKMT2A | |
| SCHEMBL7502648 | 0.93 | TBXAS1 (1.00) | TBXAS1MEN1LMNAKMT2A | |
| Dazoxiben SCHEMBL8372980 | 0.92 | TBXAS1 (0.85) | TBXAS1MEN1LMNAKMT2A | |
| SCHEMBL22749387 | 0.91 | TBXAS1 (0.90) | TBXAS1MEN1LMNAKMT2AKDM4E | |
| SCHEMBL8685423 | 0.88 | TBXAS1 (0.80) | TBXAS1MEN1LMNAKMT2A | |
| SCHEMBL8690308 | 0.87 | TBXAS1 (0.78) | TBXAS1MEN1LMNAKMT2AKDM4E | |
| SCHEMBL3005716 | 0.87 | TBXAS1 (1.00) | TBXAS1MEN1LMNAKMT2AKDM4E | |
| SCHEMBL8690701 | 0.85 | TBXAS1 (0.75) | TBXAS1MEN1LMNAKMT2AKDM4E | |
| Hydrochloric Acid SCHEMBL10751470 | 0.84 | TBXAS1 (0.97) | TBXAS1MEN1LMNAKMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1439 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025184468-A9 | MEASUREMENT OF URINE THROMBOXANE METABOLITES TO PREDICT SURVIVAL | UNIVERSITY OF MASSACHUSETTS (US) | 2025-10-16 | — | — | WO | claimed |
| US-20200187851-A1 | PERIODONTAL DISEASE STRATIFICATION AND USES THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2020-06-18 | — | — | US | claimed |
| US-10570103-B2 | Heterocyclic compounds useful in the treatment of disease | EPIGEN BIOSCIENCES, INC. (US) | 2020-02-25 | — | — | US | claimed |
| US-20190135767-A1 | Heterocyclic Compounds Useful In The Treatment Of Disease | EPIGEN BIOSCIENCES, INC. (US) | 2019-05-09 | — | — | US | claimed |
| CN-106397171-A | Synthesis method of dazoxiben medicine intermediate 4-(2-chloroethoxy) phenylformic acid | 厦门安普顿信息科技有限公司 | 2017-02-15 | — | — | CN | claimed |
| CN-105481686-A | Synthetic method of Dazoxiben drug intermediate 4-(2-chloroethoxy)benzoic acid | CHENGDU QIESITE TECH CO LTD | 2016-04-13 | — | — | CN | claimed |
| US-9221779-B2 | Serotonin reuptake inhibitors as drugs having peripheral-system-restricted activity | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2015-12-29 | — | — | US | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| EP-1675578-B9 | INHIBITORS OF GLUTAMINYL AND GLUTAMATE CYCLASES FOR THE TREATMENT OF THE NEURODEGENERATIVE DISEASES FBD AND FDD | PROBIODRUG AG (DE) | 2014-06-25 | — | — | EP | claimed |
| CN-103664847-A | Serotonin reuptake inhibitors as drugs having peripheral-system-restricted activity | UNIV RAMOT | 2014-03-26 | — | — | CN | claimed |
| EP-0266979-A2 | Therapeutic agents | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1988-05-11 | — | — | EP | claimed |
| EP-0266980-A2 | Pharmaceutical compositions, comprising a 2,4-diphenyl-1,3-dioxane derivative and an inhibitor of thromboxane A2 synthesis | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1988-05-11 | — | — | EP | claimed |
| EP-0256805-A2 | Pharmaceutical compositions for the treatment of occlusive vascular diseases | GLAXO GROUP LIMITED (GB) | 1988-02-24 | — | — | EP | claimed |
| EP-0191771-A4 | Automatic injector assembly. | SURVIVAL TECHNOLOGY (US) | 1987-12-07 | — | — | EP | claimed |
| WO-1986006965-A1 | INJECTION METHOD AND APPARATUS WITH ELECTRICAL BLOOD ABSORBING STIMULATION | SURVIVAL TECHNOLOGY, INC. (US) | 1986-12-04 | — | — | WO | claimed |
| WO-1986005095-A1 | t-PA COMPOSITION AND METHOD OF GETTING INTO BLOOD STREAM | SURVIVAL TECHNOLOGY, INC. (US) | 1986-09-12 | — | — | WO | claimed |
| EP-0191771-A1 | Automatic injector assembly. | SURVIVAL TECHNOLOGY (US) | 1986-08-27 | — | — | EP | claimed |
| EP-0191056-A1 | t-PA COMPOSITION AND METHOD OF GETTING INTO BLOOD STREAM | SURVIVAL TECHNOLOGY, INC. (US) | 1986-08-20 | — | — | EP | claimed |
| WO-1986001120-A1 | INJECTION METHOD AND APPARATUS WITH ELECTRICAL BLOOD ABSORBING STIMULATION | SURVIVAL TECHNOLOGY, INC. (US) | 1986-02-27 | — | — | WO | claimed |
| WO-1986001104-A1 | t-PA COMPOSITION AND METHOD OF GETTING INTO BLOOD STREAM | SURVIVAL TECHNOLOGY, INC. (US) | 1986-02-27 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190135767-A1 | Heterocyclic Compounds Useful In The Treatment Of Disease | LPAR1, LPAR2, LPAR4 | TBXAS1 233/4885MEN1 2773/4885LMNA 1097/4885 |
| US-10570103-B2 | Heterocyclic compounds useful in the treatment of disease | LPAR1, LPAR2, LPAR4 | TBXAS1 233/4885MEN1 2773/4885LMNA 1097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.